The goal of the proposed research remains the elucidation of neurobiological mechanisms underlying mediation of drug-abuse and psychotic states by the phencyclidine (PCP)/NMDA receptor-channel complex. During the initial project period we identified specific PCP receptors in brain membranes and provided biochemical and pharmacological evidence that these sites mediate the unique actions of PCP-related drugs. All PCP-like agents are noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) type of excitatory amino acid receptor; the PCP receptor is situated within the NMDA receptor-gated ion channel. Therefore binding characteristics of ligands to the PCP receptor are sensitive to the state of the ion channel, and elucidation of mechanisms of action of PCP-related drugs requires determination of mechanisms governing regulation of NMDA receptor activation by its agonists, antagonists and modulators. During the previous project period we published evidence from PCP receptor binding studies carried out at equilibrium and by kinetic techniques which support a complex model of the interaction of PCP-related drugs with the NMDA receptor channel. We reported that PCP receptor binding characteristics cannot be explained on the basis of a single affinity component of binding in equilibrium studies or by single exponentials of association/dissociation in kinetic studies, as would be predicted by the """"""""open-channel blocker"""""""" model of PCP action proposed by others. We were able to account for our findings on the basis of a multistate model of NMDA receptor activation in which PCP receptor ligands bind differentially to open and to closed, agonist-associated states of the NMDA channel, and to demonstrate a requirement for multiple molecules of agonist for NMDA channel activation. These techniques now provide us with an analytical tool which will serve as a methodological focus for further elucidation of mechanisms governing NMDA receptor activation and PCP effects in the proposed research. We shall determine the mechanistic basis of the actions of polyamines upon the NMDA/PCP receptor and detect whether their effects are mediated by independent mechanisms or by modulation of the effects of other regulators. The mechanistic basis of the biochemical and functional heterogeneity of NMDA/PCP receptors in cerebellum vs. forebrain will be determined. Acute PCP effects, mediated by the PCP receptor, include induction of a psychotic state in normal subjects closely resembling schizophrenia, and specific exacerbation of illness in schizophrenics. The mechanistic relationship between PCP-induced psychosis and schizophrenia will be determined by studies comparing the detailed characteristics of PCP receptor binding and mechanisms governing NMDA receptor activation in postmortem brain samples derived from schizophrenics vs. matched controls. Together, the proposed studies will significantly advance our understanding of an important mechanism underlying drug abuse and psychiatric illness.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003383-11
Application #
2116737
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1982-07-01
Project End
1996-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
11
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Kantrowitz, Joshua T; Hoptman, Matthew J; Leitman, David I et al. (2015) Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. J Neurosci 35:14909-21
Kantrowitz, J T; Hoptman, M J; Leitman, D I et al. (2014) The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. Psychol Med 44:25-36
Kantrowitz, J T; Scaramello, N; Jakubovitz, A et al. (2014) Amusia and protolanguage impairments in schizophrenia. Psychol Med 44:2739-48
Guilfoyle, David N; Gerum, Scott V; Sanchez, Jamie L et al. (2013) Functional connectivity fMRI in mouse brain at 7T using isoflurane. J Neurosci Methods 214:144-8
Javitt, Daniel C (2012) Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol :367-99
Kantrowitz, Joshua; Javitt, Daniel C (2012) Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 25:96-102
Moghaddam, Bita; Javitt, Daniel (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4-15
Javitt, Daniel C; Zukin, Stephen R; Heresco-Levy, Uriel et al. (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38:958-66
Balla, Andrea; Schneider, Samantha; Sershen, Henry et al. (2012) Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia. Eur Neuropsychopharmacol 22:902-10
Javitt, Daniel C; Schoepp, Darryle; Kalivas, Peter W et al. (2011) Translating glutamate: from pathophysiology to treatment. Sci Transl Med 3:102mr2

Showing the most recent 10 out of 61 publications